Abstract:Objective To explore the therapeutic effect of selective antagonist-AM630 of cannabionid receptor 2 (CB2) in treatment of the titanium particles-induced inflammatory osteolysis. Methods Forty-five female BALB/c mice, 6-8 weeks old, were involved in the study, of which 15 mice were used as skull donors and the rest experimental animals were randomly divided into three groups, ie, black group, control group and treatment group, 10 mice per group.The mice model with air-pouch osteolysis induced by the titanium particles were established.The mice in the treatment group were injected with CB2 selective antagonist-AM630 (200 μg · kg-1 · d-1) intraperitoneally from two days before establishment of the air-pouch osteolysis model to two weeks after establishment of the model.Then, the mice were sacrificed and the pouch tissues were collected for molecular and histological analyses.The pouch membrane thickness and cell infiltration were tested by using computerized image analysis system and HE staining respectively.Osteoclast-like cells in the pouch membrane were determined by using tartrate-resistant acid phosphatase (TRAP) staining.Quantitative real-time polymerase chain reaction (RT-PCR) was employed to detect the mRNA levels of CB2, IL-1 β, TNF-α, receptor activator of NF-κB ligand (RANKL)and receptor activator of NF-κB (RANK).Results There exhibited apparent erythematous and oedematous changes in the control group, which was mitigated around the bone implants with AM630 treatment.Quantitative image analysis of the histological sections revealed significant difference of the pouch membrane thickness among three groups, (192.2 ± 19.4) μm in control group, (88.5 ± 14.7) μm in blank group and (122.1 ± 15.2) μm in treatment group (F = 101.74, P ＜ 0.05).Intensive TRAP staining was identified much in the control group but markedly reduced after AM630 treatment in the pouch tissues.RT-PCR showed that titanium particle stimulation could enhance the expressions of CB2, IL-1 β, TNF-α, RANKL and RANK gene in the air pouch tissues.However, the mRNA levels of these genes were markedly reduced after AM630 treatment, with statistical difference compared with control group (P ＜ 0.05). Conclusions CB2 selective antagonist AM630 can inhibit the process of titanium particlesstimulated inflammatory reaction and osteoclast activation.Therefore, CB2 represents a new suitable therapeutic candidate for the prevention and treatment of aseptic loosening of the artificial joint.

Cannabinoid Receptor-2 Selective Antagonist Negatively Regulates Receptor Activator of Nuclear Factor Kappa B Ligand Mediated Osteoclastogenesis

The Role of Cannabinoid Receptor 2 Selective Antagonist in Osteoclast Differentiation of RAW264.7 Cells

Inhibitory Effects of AM630 on Inflammatory Osteolysis Induced by Titanium Particles

Mineralizing Solution and Dexamethasone Enhance Receptor Activator for NF-κB Ligand Expression in Rat Bone Marrow Stromal Cells

Role of Cannabinoid Receptor 2 Selective Antagonist in Titanium Particles-Induced Inflammatory Osteolysis

Inhibition Of Titanium Particle-Induced Inflammatory Osteolysis Through Inactivation Of Cannabinoid Receptor 2 By Am630

Cannabinoid Receptor 2 Agonist Prevents Local and Systemic Inflammatory Bone Destruction in Rheumatoid Arthritis

Effects of a Cannabinoid Receptor 2 Selective Antagonist on the Inflammatory Reaction to Titanium Particles in Vivo and in Vitro.

Recombinant Soluble Receptor Activator of Nuclear Factor-Kappab Inhibits Parathyroid Hormone-Induced Osteoclastogenesis in Vitro.

[Osteoclast Differentiation Regulated by Receptor Activator of Nuclear Factor Kappab Probably Through a Novel Signaling Pathway].

Recombinant Receptor Activator of Nuclear Factor Κb Exhibits More Marked Inhibitory Effects on Osteoclasts Compared with Recombinant Osteoprotegerin in Vitro and in Vivo.

Protection against titanium particle induced osteolysis by cannabinoid receptor 2 selective antagonist.

Murine Rank Protein'S Inhibition of Bone Resorption

Activation Of Cannabinoid Receptor Cb2 Regulates Osteogenic And Osteoclastogenic Gene Expression In Human Periodontal Ligament Cells

BIX01294 suppresses osteoclast differentiation on mouse macrophage-like Raw264.7 cells.

Effect of JAK2/STAT3 Signaling Pathway on RANKL-induced Osteoclastogenesis in RAW264.7 Cells

Curcumol Suppresses RANKL-induced Osteoclast Formation by Attenuating the JNK Signaling Pathway

Selective Beta 2-Adrenoreceptor Signaling Regulates Osteoclastogenesis Via Modulating Rankl Production And Neuropeptides Expression In Osteocytic Mlo-Y4 Cells

Ellagic Acid Blocks RANKL-RANK Interaction and Suppresses RANKL-induced Osteoclastogenesis by Inhibiting RANK Signaling Pathways

Functional Identification Of Three Receptor Activator Of Nf-Kappa B Cytoplasmic Motifs Mediating Osteoclast Differentiation And Function

Effectso f the CB2 in hibitor AM630 on nanoscale titaniu m particles -induced Ana -1 cell s